Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ALIZADEH ALI AKBAR; Jafari Behzad; DASTMALCHI SIAVOUSH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Advanced Pharmaceutical Bulletin Year:2023 | Volume:13 | Issue:1 Page(s): 113-122

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches

Author(s)

ALIZADEH ALI AKBAR | Jafari Behzad | DASTMALCHI SIAVOUSH | Issue Writer Certificate

Keywords

S1P agonists

Drug repurposing

Multiple sclerosis

Molecular dynamics simulations

Similarity network analysis

Abstract

Purpose: Drug repurposing is an approach successfully used for discovery of new therapeutic applications for the existing drugs. The current study was aimed to use the combination of in silico methods to identify FDA-approved drugs with possible S1P1 agonistic activity useful in Multiple sclerosis (MS). Methods: For this, a 3D-QSAR model for the known 21 S1P1 agonists were generated based on 3D-QSAR approach and used to predict the possible S1P1 agonistic activity of FDA-approved drugs. Then, the selected compounds were screened by docking into S1P1 and S1P3 receptors to select the S1P1 potent and selective compounds. Further evaluation was carried out by molecular dynamics (MD) simulation studies where the S1P1 binding energies of selected compounds were calculated. Results: The analyses resulted in identification of cobicistat, benzonatate and brigatinib as the selective and potent S1P1 agonists with the binding energies of-85. 93,-69. 77 and-67. 44 kcal. mol-1, calculated using MM-GBSA algorithm based on 50 ns MD simulation trajectories. These values are better than that of siponimod (-59. 35 kcal mol-1), an FDA approved S1P1 agonist indicated for MS treatment. Furthermore, Similarity network analysis revealed that cobicistat and brigatinib are the most structurally favorable compounds to interact with S1P1. Conclusion: The findings in this study revealed that cobicistat and brigatinib can be evaluated in experimental studies as potential S1P1 agonist candidates useful in the treatment of MS.

Cites

No record.

References

Drug Central 2021 supports drug discovery and repositioning

Cite

APA: Copy

ALIZADEH, ALI AKBAR, Jafari, Behzad, & DASTMALCHI, SIAVOUSH. (2023). Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches. ADVANCED PHARMACEUTICAL BULLETIN, 13(1), 113-122. SID. https://sid.ir/paper/1089852/en

Vancouver: Copy

ALIZADEH ALI AKBAR, Jafari Behzad, DASTMALCHI SIAVOUSH. Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches. ADVANCED PHARMACEUTICAL BULLETIN[Internet]. 2023;13(1):113-122. Available from: https://sid.ir/paper/1089852/en

IEEE: Copy

ALI AKBAR ALIZADEH, Behzad Jafari, and SIAVOUSH DASTMALCHI, “Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches,” ADVANCED PHARMACEUTICAL BULLETIN, vol. 13, no. 1, pp. 113–122, 2023, [Online]. Available: https://sid.ir/paper/1089852/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops